文献速递瓣膜病与结构性心脏病

SOLVE-TAVI试验1年随访:麻醉策略与瓣膜类型对TAVR临床结局的影响

Impact of Anesthesia Strategy and Valve Type on Clinical Outcomes After Transcatheter Aortic Valve Replacement.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

SOLVE-TAVI随机试验采用2×2析因设计,纳入447例中高危重度症状性主动脉瓣狭窄患者,比较经股动脉TAVR中自膨胀瓣膜与球囊扩张瓣膜、全麻与清醒镇静的1年临床结局。结果显示瓣膜类型间复合终点(全因死亡、卒中、中重度瓣周漏、永久起搏器植入)发生率相似(38.3% vs 40.4%,HR 0.94,95%CI 0.70-1.26,P=0.66),麻醉策略间复合终点(全因死亡、卒中、心梗、急性肾损伤)发生率亦相似(25.7% vs 23.8%,HR 1.09,95%CI 0.76-1.57,P=0.63)。

要点

  • 新一代自膨胀瓣膜与球囊扩张瓣膜在1年复合终点上无显著差异。
  • 全麻与清醒镇静在1年复合终点上无显著差异。
  • 中高危经股动脉TAVR患者中两种策略的1年临床结局相当。

核心结论

  • 在中高危经股动脉TAVR患者中,新一代自膨胀瓣膜与球囊扩张瓣膜、清醒镇静与全麻在1年复合临床终点上显示相似的临床结局。

研究设计与样本

  • SOLVE-TAVI为随机对照试验,采用2×2析因设计,在7个中心纳入447例中高危重度症状性主动脉瓣狭窄患者。
  • 患者随机分配至经股动脉TAVR使用自膨胀瓣膜(Evolut R)或球囊扩张瓣膜(Sapien 3),以及清醒镇静或全麻。

主要发现

  • 瓣膜比较策略中,球囊扩张瓣膜组与自膨胀瓣膜组1年复合终点(全因死亡、卒中、中重度瓣周漏、永久起搏器植入)发生率相似(38.3% vs 40.4%;HR 0.94;95%CI 0.70-1.26;P=0.66)。
  • 麻醉比较策略中,全麻组与清醒镇静组1年复合终点(全因死亡、卒中、心肌梗死、急性肾损伤)发生率相似(25.7% vs 23.8%;HR 1.09;95%CI 0.76-1.57;P=0.63)。

临床怎么用

  • 对于中高危经股动脉TAVR患者,选择新一代自膨胀瓣膜或球囊扩张瓣膜、以及清醒镇静或全麻,均可考虑,1年临床结局相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The randomized SOLVE-TAVI (compariSon of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthesia in Transcatheter Aortic Valve Implantation) trial compared newer-generation self-expanding valves (SEV) and balloon-expandable valves (BEV) as well as local anesthesia with conscious sedation (CS) and general anesthesia (GA) in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR). Both strategies showed similar outcomes at 30 days. OBJECTIVES: The purpose of this study was to compare clinical outcomes during 1-year follow-up in the randomized SOLVE-TAVI trial. METHODS: Using a 2 × 2 factorial design 447 intermediate- to high-risk patients with severe, symptomatic aortic stenosis were randomly assigned to transfemoral TAVR using either the SEV (Evolut R, Medtronic Inc., Minneapolis, Minnesota) or the BEV (Sapien 3, Edwards Lifesciences, Irvine, California) as well as CS or GA at 7 sites. RESULTS: In the valve-comparison strategy, rates of the combined endpoint of all-cause mortality, stroke, moderate or severe paravalvular leakage, and permanent pacemaker implantation were similar between the BEV and SEV group (n = 84, 38.3% vs. n = 87, 40.4%; hazard ratio: 0.94; 95% confidence interval: 0.70 to 1.26; p = 0.66) at 1 year. Regarding the anesthesia comparison, the combined endpoint of all-cause mortality, stroke, myocardial infarction, and acute kidney injury occurred with similar rates in the GA and CS groups (n = 61, 25.7% vs. n = 54, 23.8%; hazard ratio: 1.09; 95% confidence interval: 0.76 to 1.57; p = 0.63). CONCLUSIONS: In intermediate- to high-risk patients undergoing transfemoral TAVR, newer-generation SEV and BEV as well as CS and GA showed similar clinical outcomes at 1 year using a combined clinical endpoint. (SecOnd-generation seLf-expandable Versus Balloon-expandable Valves and gEneral Versus Local Anesthesia in TAVI [SOLVE-TAVI]; NCT02737150).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Feistritzer HJ, Kurz T, Stachel G, et al. Impact of Anesthesia Strategy and Valve Type on Clinical Outcomes After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2021. PMID: 33926657. doi:10.1016/j.jacc.2021.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。